Patent 10081624 was granted and assigned to Takeda Pharmaceutical Company on September, 2018 by the United States Patent and Trademark Office.
The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound.